Lisata Therapeutics Q4 2025 Earnings Report

Lisata Therapeutics EPS Results

• Actual EPS: -$0.33
• Consensus EPS: -$0.74
• Beat/Miss: Beat by +$0.41
• One Year Ago EPS: N/A

Lisata Therapeutics Revenue Results

• Actual Revenue: $0.10 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lisata Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/12/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Lisata Therapeutics (NASDAQ:LSTA) (NASDAQ:LSTA) is a clinical-stage biotechnology company focused on developing therapies for the treatment of cancer. The company’s research is centered on improving the delivery of anticancer agents into solid tumors and addressing the biological barriers that can limit the effectiveness of conventional cancer treatments.

Lisata’s lead investigational product is certepetide, formerly known as LSTA-1. Certepetide is a tumor-penetrating peptide designed to selectively bind to neuropilin-1, a receptor associated with tumor vasculature and the tumor microenvironment. By engaging this target, the therapy is intended to improve the penetration and distribution of concurrently administered cancer treatments within solid tumors and potentially support antitumor immune activity.

Lisata is evaluating certepetide in combination with other anticancer therapies through clinical development programs involving solid tumors, including pancreatic cancer and other difficult-to-treat malignancies. The company’s operations are focused primarily on research, development and clinical testing rather than the sale of marketed pharmaceutical products. Lisata was formerly known as Caladrius Biosciences and adopted its current name in 2021. Its corporate headquarters are in Basking Ridge, New Jersey.